Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarbose effect in metabolic syndrome
IRCT20130924014752N5Phase 3Completed
- Sponsor
- Isfahan Endocrine and Metabolism Research Center
- Start
- Mar 2017
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cardiometabolic risk (CMR) and obesity comparing Acarbose with Placebo (2 arms). Primary endpoints: Waist circumference, Low-density lipoprotein cholesterol and 4 more. Started Mar 2017; status: completed.
02
Drugs
acarbose
03
Conditions
cardiometabolic risk (CMR)obesity
Beyond the preview
Go deeper on IRCT20130924014752N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130924014752N5.